2 Houston cleantech companies named to top 10 ranking of innovative energy

high impact

Fervo Energy and Syzygy Plasmonics were recognized for their energy innovation. Photo via Getty Images

A pair of Houston energy startups have been named among the 10 most innovative energy companies for 2024.

Fast Company magazine just placed Fervo Energy and Syzygy Plasmonics on its energy innovation list. In all, 606 companies and organizations across a variety of industries were recognized for “reshaping industries and culture.”

Fervo produces carbon-free geothermal energy. Its existing geothermal project is in Nevada, and it’s building a geothermal project in Utah. The company recently raised $244 million.

“Solar and wind are cheap, but they don’t provide the kind of always-on dispatchable electricity that hydropower, hydrogen, and nuclear do; even at current high prices, enhanced geothermal is still cheaper than those other sources,” Fast Company notes.

The Fast Company accolade comes shortly after Time and Statista named Fervo one of the top greentech companies for 2024.

By relying on light rather than combustion to generate chemical reactions, Syzygy is taking on the use of fossil fuels in the chemical industry, Fast Company points out. Fossil fuels account for about 18 percent of the world’s industrial CO2 emissions.

Fast Company outlines some of Syzygy’s accomplishments in 2023:

  • Gained an undisclosed amount of funding from Mitsubishi Heavy Industries.
  • Completed its Pearland manufacturing facility.
  • Wrapped up 1,000 cumulative hours of testing on its ammonia-splitting reactor cell, capable of producing 200 kilograms of hydrogen per day.
CodeLaunch named its winner — and more Houston innovation news. Photo courtesy of Honeycomb

Houston startup secures bank partnership, energy tech co. wins competition, and more

short stories

Houston startup founders have been moving and shaking in the local innovation ecosystem — from being recognized for their out-of-this-world innovation to big wins.

In this roundup of Houston startup and innovation news, a Houston company snags a major partnership, an energy tech startup wins big on stage, and more.

The Postage gets a new partner

The Postage platform will be available to AmBank Company's employees, customers, and their families. Photo courtesy of The Postage

A Houston tech platform that streamlines estate and legacy planning has entered into a partnership with AmBank Company — American State Bank, American Investment & Trust, and Perspective Insurance — in Sioux Center, Iowa. The bank will deliver The Postage's services to its employees, customers, and their families.

The Postage unique platform allows users important information organizational tools, as well as state-specific will document creation. The technology also allows users to share meaningful family memories, write future messages, and collaborate with loved ones of their choosing.

"Community is at the core of everything American State Bank does. They exemplify that by supporting their customers through the myriad of choices that arise while navigating their financial lives. The Postage fits right into that, and we are thrilled to share our platform with their employees and customers in their planning and organization efforts," says Emily Cisek, CEO and co-founder of The Postage, in a news release. "We hope to grow awareness of the family-driven digital solution and provide AmBank's customers the opportunity to gain control and safeguard their critical information. We look forward to providing AmBank's customers with the guidance they need to protect their wealth and wisdom now and for generations to come."

The partnership, which rolled out last month, was announced as American State Bank and the family of brands celebrated 50 years of business.

"Our commitment to delivering outstanding service and top-notch products to our customers, colleagues, and community has been unwavering for over half a century," says Joel Westra, AmBank first vice president. "This partnership allows us to extend our digital services while staying true to our core values of connection and community.

"Our team has witnessed the struggles of families coping with losing a loved one, we recognized the need for a service like The Postage," he continues. "Far too often, people are uncertain about the next steps, the whereabouts of important documents, and even their loved one's final wishes. We recognize that to prevent these challenges, families need help navigating difficult conversations and guidance on how to get started with their planning, which The Postage provides."

E360 wins Houston startup competition

E360 and Honeycomb Software share the win at the 2023 Houston CodeLaunch event. Photo by Natalie Harms/InnovationMap

CodeLaunch, a traveling seed-stage accelerator, hosted its second Houston startup pitch competition last week, and a Houston energy efficiency startup emerged victorious.

E360 won the top prize at the event on March 2. The program paired six finalists with consultant development teams to pitch and compete for up to $150,000. The startup's technology is a holistic building solution that monitors both the energy efficiency and indoor air quality of commercial buildings.

“The goal I pursued at CodeLaunch was to meet industry leaders and investors who can help take the product to the next level," says Mat Bonassera, chief enterprise architect at E360, in a news release. “The vast majority of buildings are both incredibly inefficient as well as dangerous to their occupants, due to the dangerous levels of compounds in the air.

"We solve both these complex problems at the same time," he continues. "This is unheard of in our industry. We do this by monitoring vast sums of IOT data and then using Machine Learning and real-time monitoring we adjust the building to optimize its performance. This is a revolutionary way to look at commercial buildings."

E360 shares the win with its partner development team Honeycomb Software, an international custom software development company. The provided hands-on support to E360 scale during a two-day hackathon held February 25 and 26.

“The desire to promote energy efficiency of the buildings and the sustainability in business influenced our decision of whom to work with during the Hackathon," says Oleksandr Semeniuk, CEO of Honeycomb Software, in the release. "Our team worked tirelessly to expand the functionality of E360, and this victory is a testament to their hard work and dedication."

Axiom named among most innovative companies

KBR is one of Axiom Space's partners on its new NASA-sanctioned ISS project. Photo via AxiomSpace.com

Fast Company named it's 50 most innovative companies — and Axiom Space, a Houston-based commercial, full-service orbital mission provider, was named No. 49 on the list. It was also recognized as one of the most innovative space tech companies "for going to space without a chaperone," per the magazine.

The article recognized several of Axiom's accomplishments, including:

  • Managing the first all-private mission to the International Space Station in April of 2022. The mission sent a four-person crew into space for 17 days.
  • Developing plans to expand the international community of space explorers, including Italy, Canada, New Zealand, and others.
  • Building a module to attach to the ISS, which is progress toward the world’s first commercial free-floating space station.

“In the space business, there’s a big focus on the transportation, the rockets,” Michael Suffredini, president and CEO of Axiom, tells Fast Company. “But if you think about the railroads that were built across the U.S., they were built to serve a destination. Without a reason to go somewhere, they wouldn’t exist. We’re building the destination in space—the real estate to allow multiple businesses to operate in low-Earth orbit and take advantage of the microgravity environment.”

NASA also makes the ranking for "showing that a public space program can still do big things," according to the list.

Calling all student-founded startups and businesses

Rice and UH have programs for startup and small business entrepreneurs. Photo via uh.edu

Rice University and the University of Houston have upcoming deadlines for their summer accelerators. The summer programs all operate in coordination with each other and offer support for student, faculty, or staff founders and their startups and small businesses.

The four programs, and their focus and application deadlines, are as follows:

  • Rice's OwlSpark is focused on early-stage startup teams with at least one Rice student, faculty, or staff founders to grow from innovation to commercialization. Apply by March 13.
  • UH's RedLabs is focused on early-stage startup teams with at least one UH student, faculty, or staff founders to grow from innovation to commercialization. Apply by March 31.
  • Rice's BlueLaunch is focused on non-tech small business entrepreneurs who are either student, faculty, or staff at Rice. Apply by March 13.
  • UH's Red Launch is focused on non-tech small business entrepreneurs who are either student, faculty, or staff at UH. Apply by March 31.

Dr. Peter Hotez and Dr. Maria Elena Bottazzi have been recognized by Fast Company for their leadership in developing low-cost COVID vaccine. Photo courtesy of Texas Children's

Houston doctors recognized among top creative leaders in business

winners

This week, Fast Company announced its 14th annual list of Most Creative People in Business — and two notable Houstonians made the cut.

Dr. Peter Hotez and his fellow dean of the National School of Tropical Medicine at Baylor College of Medicine, Dr. Maria Elena Bottazzi, were named among the list for “open sourcing a COVID-19 Vaccine for the rest of the world.” The list, which recognizes individuals making a cultural impact via bold achievements in their field, is made up of influential leaders in business.

Hotez and Bottazzi are also co-directors for the Texas Children's Hospital's Center for Vaccine Development -one of the most cutting-edge vaccine development centers in the world. For the past two decades it has acquired an international reputation as a non-profit Product Development Partnership (PDP), advancing vaccines for poverty-related neglected tropical diseases (NTDs) and emerging infectious diseases of pandemic importance. One of their most notable achievements is the development of a vaccine technology leading to CORBEVAX, a traditional, recombinant protein-based COVID-19 vaccine.

"It's an honor to be recognized not only for our team's scientific efforts to develop and test low cost-effective vaccines for global health, but also for innovation in sustainable financing that goes beyond the traditional pharma business model," says Hotez in a statement.

The technology was created and engineered by Texas Children's Center for Vaccine Development specifically to combat the worldwide problem of vaccine access and availability. Biological E Limited (BE) developed, produced and tested CORBEVAX in India where over 60 million children have been vaccinated so far.

Earlier this year, the doctors were nominated for the 2022 Nobel Peace Prize for their research and vaccine development of the vaccine. Its low cost, ease of production and distribution, safety, and acceptance make it well suited for addressing global vaccine inequity.

"We appreciate the recognition of our efforts to begin the long road to 'decolonize' the vaccine development ecosystem and make it more equitable. We hope that CORBEVAX becomes one of a pipeline of new vaccines developed against many neglected and emerging infections that adversely affect global public health," says Bottazzi in the news release from Texas Children's.

Fast Company editors and writers research candidates for the list throughout the year, scouting every business sector, including technology, medicine, engineering, marketing, entertainment, design, and social good. You can see the complete list here

.

Solugen has been named among the most innovative companies in the world — and was deemed the No. 1 most innovative manufacturers. Photo via Getty Images

Houston startup ranks as a top innovative company in the world

No. 1

A Houston biotech startup is now in rarified air.

Solugen ranks second on Fast Company’s 2022 list of the 50 most innovative companies in the world. It also sits at No. 1 on the magazine’s list of the world’s most innovative manufacturers.

Solugen’s process converts corn syrup into industrial chemicals, cutting down on carbon emissions generated by traditional production of chemicals. Carbon dioxide from chemical production is one of the biggest contributors to industrial greenhouse gas emissions.

“Right now, the $6 trillion chemicals industry relies on oil, natural gas, and coal to make ingredients used in everything from laundry detergent and running shoes to fertilizer. It’s a dirty process,” Fast Company reported last December.

According to Fast Company, Solugen’s process for producing a chemical uses nearly all of the feedstock put into it.

“The carbon-negative process and Solugen’s ability to sell flexible amounts of chemicals to companies looking to lower their own footprint have helped the company make inroads in a traditionally slow-moving industry,” the magazine says.

Fast Company notes that Solugen launched in 2016 with four chemicals and another 17 in development. The chemicals are being used in water treatment, in concrete production to reduce cement use, and in agriculture to deliver nutrients to crops, the magazine says.

Last year, Solugen announced it raised $357 million in a Series C round, catapulting it to “unicorn” status. The Series C round bumped up the startup to a valuation of $1.8 billion, pushing it well past the $1 billion mark required for a unicorn designation.

“This fundraising round allows us to continue expanding the footprint of our Bioforge technology to give industries the products they need to reduce emissions in their existing supply chains, without compromising on performance or economics,” Sean Hunt, co-founder and chief technology officer of Solugen, said in a news release about the $357 million round.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice team keeps CO2-to-fuel devices running 50 times longer in new study

Bubbling Up

In a new study published in the journal Science, a team of Rice University researchers shared findings on how acid bubbles can improve the stability of electrochemical devices that convert carbon dioxide into useful fuels and chemicals.

The team led by Rice associate professor Hoatian Wang addressed an issue in the performance and stability of CO2 reduction systems. The gas flow channels in the systems often clog due to salt buildup, reducing efficiency and causing the devices to fail prematurely after about 80 hours of operation.

“Salt precipitation blocks CO2 transport and floods the gas diffusion electrode, which leads to performance failure,” Wang said in a news release. “This typically happens within a few hundred hours, which is far from commercial viability.”

By using an acid-humidified CO2 technique, the team was able to extend the operational life of a CO2 reduction system more than 50-fold, demonstrating more than 4,500 hours of stable operation in a scaled-up reactor.

The Rice team made a simple swap with a significant impact. Instead of using water to humidify the CO2 gas input into the reactor, the team bubbled the gas through an acid solution such as hydrochloric, formic or acetic acid. This process made more soluble salt formations that did not crystallize or block the channels.

The process has major implications for an emerging green technology known as electrochemical CO2 reduction, or CO2RR, that transforms climate-warming CO2 into products like carbon monoxide, ethylene, or alcohols. The products can be further refined into fuels or feedstocks.

“Using the traditional method of water-humidified CO2 could lead to salt formation in the cathode gas flow channels,” Shaoyun Hao, postdoctoral research associate in chemical and biomolecular engineering at Rice and co-first author, explained in the news release. “We hypothesized — and confirmed — that acid vapor could dissolve the salt and convert the low solubility KHCO3 into salt with higher solubility, thus shifting the solubility balance just enough to avoid clogging without affecting catalyst performance.”

The Rice team believes the work can lead to more scalable CO2 electrolyzers, which is vital if the technology is to be deployed at industrial scales as part of carbon capture and utilization strategies. Since the approach itself is relatively simple, it could lead to a more cost-effective and efficient solution. It also worked well with multiple catalyst types, including zinc oxide, copper oxide and bismuth oxide, which are allo used to target different CO2RR products.

“Our method addresses a long-standing obstacle with a low-cost, easily implementable solution,” Ahmad Elgazzar, co-first author and graduate student in chemical and biomolecular engineering at Rice, added in the release. “It’s a step toward making carbon utilization technologies more commercially viable and more sustainable.”

A team led by Wang and in collaboration with researchers from the University of Houston also recently shared findings on salt precipitation buildup and CO2RR in a recent edition of the journal Nature Energy.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings